ReviewNature reviews. Microbiology2024
Pertussis vaccines, epidemiology and evolution.
Review in Nature reviews. Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global seroepidemiology of pertussis: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Limited protective immunity to respiratory syncytial virus and pertussis among adults and healthcare workers in South Korea: A seroepidemiologic study.Human vaccines & immunotherapeutics · 2026Article
- Effectiveness of DTaP-IPV//PRP-T vaccine against pertussis among infants and toddlers in Zhejiang, China: a retrospective cohort study.Emerging microbes & infections · 2026Article
- Impact of the COVID-19 pandemic on the global burden of pertussis: An analysis of trends and the emergence of an immunity gap.Human vaccines & immunotherapeutics · 2026Article
- Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficientEmerging microbes & infections · 2026Article
- Article
- Quantifying the impact of vaccination on pertussis dynamics in Sweden.PLoS computational biology · 2026Article
- Global phylogenomics of Bordetella pertussis ST2 reveals regional heterogeneity in China and lineage-specific genome evolution.BMC genomics · 2026Article
- Pre-existing antibodies predict protection while mucosal inflammation correlates with symptomaticmedRxiv : the preprint server for health sciences · 2026Article
- A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.medRxiv : the preprint server for health sciences · 2026Article
- Study on the resurgence of pertussis based on a stage-structured dynamic model.Infectious Disease Modelling · 2026Article
- C-terminal domain of the filamentous hemagglutinin FhaB is crucial for interaction ofbioRxiv : the preprint server for biology · 2026Article
- Development and validation of a clinical severity prediction model for hospitalized children with pertussis.BMC infectious diseases · 2026Article
- Global patterns of pertussis incidence and vaccination strategies: implications of divergent surveillance data.NPJ vaccines · 2026Article
- Pertussis resurgence after the COVID-19 pandemic in four Western Pacific Countries and the USA, highlighting the 2025 outbreak in Japan.Scientific reports · 2026Article
- Sudden pertussis outbreaks in Guro-gu, Seoul: epidemiological characteristics and contributing factors in 2024.Child health nursing research · 2026Article
- Global, regional, and national burden of pertussis in children aged 0-14 years from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021.Infectious diseases & immunity · 2026Article
- Spatial, temporal, and spatiotemporal analysis of pertussis in Shapingba District, China, 2014-2024.BMC infectious diseases · 2026Article
- Flow Cytometric Assessment of Pertactin- and Tetanus Toxoid-Specific B-Cell Kinetics After Tdap Booster Vaccination in Healthy Adults.Vaccines · 2026Article
- Pertussis epidemiology and seroprevalence in Wujin District, Changzhou, China, 2024.BMC infectious diseases · 2026Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis, which is caused by Bordetella pertussis, has plagued humans for at least 800 years, is highly infectious and can be fatal in the unvaccinated, especially very young infants. Although the rollout of whole-cell pertussis (wP) vaccines in the 1940s and 1950s was associated with a drastic drop in incidence, concerns regarding the reactogenicity of wP vaccines led to the development of a new generation of safer, acellular (aP) vaccines that have been adopted mainly in high-income countries. Over the past 20 years, some countries that boast high aP coverage have experienced a resurgence in pertussis, which has led to substantial debate over the basic immunology, epidemiology and evolutionary biology of the bacterium. Controversy surrounds the duration of natural immunity and vaccine-derived immunity, the ability of vaccines to prevent transmission and severe disease, and the impact of evolution on evading vaccine immunity. Resolving these issues is made challenging by incomplete detection of pertussis cases, the absence of a serological marker of immunity, modest sequencing of the bacterial genome and heterogeneity in diagnostic methods of surveillance. In this Review, we lay out the complexities of contemporary pertussis and, where possible, propose a parsimonious explanation for apparently incongruous observations.
Indexed as
Identifiers
38907021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.